Thanks for your post nextblockbuster.

I wish I had your hopes but just remember Don's promise of an IPO on NASDAQ on Zenith for Q4 2015...nothing happened and now he is doing his "pie in the sky" reverse takeover of a TSX and/or NASDAQ listed company for Zenith!!! ????????????? What a farce!

I did not listen to the presentation but I truly appreciate all of the posts and analysis on this site. So my sense was that Don was mediocre at best (this is not unusual) and somewhat evasive. Perhaps Don is beginning to realize that he needs to replace himself. IMHO DON IS THE PROBLEM FOR BOTH COMPANIES AT THIS STAGE...PARTICULARLY AT RVX. I don't really care if he stays CEO at Zenith because basically they are just barely out of the lab BUT RVX-208 IS IN PHASE 111 BETonMACE AND DON NO LONGER HAS THE CREDIBILITY TO ACHIEVE SHAREHOLDER VALUE. Keep in mind, with Don's salary he has no need to rush (and that is both a good thing for the long term and a not so good thing for the next 5 years) nor has he the need to be truly excellent in his presentations.

I'm very pleased that Dr Sweeny did an excellent job. To RVX's credit we do know that the science is in good hands internally and in terms of the steering committee. Scientific excellence is what this company is about. The problem is management.

So what we do know is that RVX completed the Hepalink deal!!! i.e. they can actually find partners. So my hope is that Ken Lebioda has made rapid progress in negotiating the next partner. We saw the share price ramp up rapidly pre Hepalink but we're not seeing those signs yet for the next deal.

Replacing Don, a NASDAQ listing, FDA approval, a new regional deal, orphan trial could all be drivers of shareholder value.

Cheers

Toinv